TrialCancer2016

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Jennifer L Beaumont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.